HK1052338A1 - Compounds for modulating the rage receptor - Google Patents

Compounds for modulating the rage receptor

Info

Publication number
HK1052338A1
HK1052338A1 HK03103492A HK03103492A HK1052338A1 HK 1052338 A1 HK1052338 A1 HK 1052338A1 HK 03103492 A HK03103492 A HK 03103492A HK 03103492 A HK03103492 A HK 03103492A HK 1052338 A1 HK1052338 A1 HK 1052338A1
Authority
HK
Hong Kong
Prior art keywords
compounds
rage
diseases
development
end products
Prior art date
Application number
HK03103492A
Other languages
English (en)
Inventor
Adnan Mjalli
Ramesh Gopalaswamy
Kwasi Avor
Christopher Wysong
Andrew Patron
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of HK1052338A1 publication Critical patent/HK1052338A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
HK03103492A 2000-05-30 2003-05-16 Compounds for modulating the rage receptor HK1052338A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20734300P 2000-05-30 2000-05-30
US09/799,317 US6613801B2 (en) 2000-05-30 2001-03-05 Method for the synthesis of compounds of formula I and their uses thereof
PCT/US2001/017251 WO2001092210A1 (fr) 2000-05-30 2001-05-25 Composes permettant de moduler le recepteur de rage

Publications (1)

Publication Number Publication Date
HK1052338A1 true HK1052338A1 (en) 2003-09-11

Family

ID=26902168

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103492A HK1052338A1 (en) 2000-05-30 2003-05-16 Compounds for modulating the rage receptor

Country Status (12)

Country Link
US (4) US6613801B2 (fr)
EP (2) EP1642888B1 (fr)
JP (1) JP4451058B2 (fr)
AT (2) ATE531688T1 (fr)
AU (2) AU780368B2 (fr)
CA (2) CA2599562A1 (fr)
DE (1) DE60112079T2 (fr)
DK (1) DK1284959T3 (fr)
ES (2) ES2373557T3 (fr)
HK (1) HK1052338A1 (fr)
MX (1) MXPA02001099A (fr)
WO (1) WO2001092210A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
ES2312461T3 (es) * 2000-07-06 2009-03-01 Array Biopharma Inc. Derivados de la tirosina como inhibidores de la fosfatasa.
WO2002070473A2 (fr) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. Derives de carboxamide utilises comme agents therapeutiques
AU2002245590B2 (en) * 2001-03-05 2006-06-29 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
EP1453531B1 (fr) * 2001-12-19 2008-05-14 Alcedo Biotech GmbH Utilisation de proteines hmgb et d'acides nucleiques codant pour celles-ci
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
BR0311767A (pt) * 2002-06-11 2005-03-08 Wyeth Corp Compostos inibidores de sulfonamida substituìda da produção de beta amilóide, suas composições e usos
GB0220216D0 (en) * 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
EP2295976A1 (fr) 2003-03-08 2011-03-16 Auvation Ltd Marqueurs du cancer colorectal
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
CN1938591B (zh) * 2004-03-18 2011-11-30 特兰斯泰克制药公司 荧光偏振分析
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
JP5188804B2 (ja) 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
UA92154C2 (ru) * 2004-08-03 2010-10-11 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
JP2008537874A (ja) 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
WO2006119510A2 (fr) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoformes d'un recepteur pour produits de glycation avancee (rage) et methodes d'identification et d'utilisation de celles-ci
WO2007044309A2 (fr) * 2005-10-05 2007-04-19 Vasix Corporation Appareil et méthode pour inhiber la formation du complexe ptag
US20080295194A1 (en) * 2007-04-02 2008-11-27 Miami University Transgenic plants with enhanced characteristics
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
MX2009013194A (es) 2007-06-14 2010-03-30 Galactica Pharmaceuticals Inc Proteinas de fusion del receptor para productos finales de glicacion avanzada.
KR20110139292A (ko) 2009-04-20 2011-12-28 화이자 인코포레이티드 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
CA2788355C (fr) 2010-02-18 2018-03-06 Devi Reddy Gohimukkula Derives de phenyl-heteroaryle et procedes d'utilisation de ceux-ci
BR112012027427A2 (pt) * 2010-04-26 2015-09-15 Nestec Sa composições nutritivas e métodos para a mudança da nutrição parenteral para a nutrição enteral
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
EP3307781B8 (fr) 2015-06-10 2020-12-02 The Broad Institute, Inc. Anticorps, composés et écrans permettant l'identification et le traitement la cachexie ou pré-cachexie
WO2019190823A1 (fr) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Sels pharmaceutiquement acceptables de [3-(4- {2-butyl-1-[4-(4-chlorophénoxy)-phényl]-1h-imidazol-4-yl} -phénoxy)-propyl]-diéthyl-amine
WO2019190822A1 (fr) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Formes cristallines de [3-(4- {2-butyl-1-[4-(4-chloro-phénoxy)-phényl]-1h-imidazol-4-yl} -phénoxy)-propyl]-diéthyl-amine
EP3864008A1 (fr) 2018-10-10 2021-08-18 vTv Therapeutics LLC Métabolites de [3-(4-{2-butyl-1-[4-(4-chloro-phénoxy)-phényl]-1h-imidazol-4-yl}-phénoxy)-propyl]-diéthyl-amine
CN111825576B (zh) * 2020-07-21 2023-10-27 安徽东凯生物科技股份有限公司 一种氨基酸制备方法
CN117843513B (zh) * 2024-03-07 2024-05-28 深圳创元生物医药科技有限公司 一种(S)-3-Carboxytyrosine的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
IL55573A0 (en) 1977-10-03 1978-12-17 Erba Carlo Spa Substituted n-(ss-alkoxy-ethyl)-n-(4-phenoxybenzyl)-dichloroacetamides and process for their preparation
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
US5202424A (en) 1984-03-19 1993-04-13 The Rockefeller University Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US4873313A (en) 1985-01-18 1989-10-10 Beckman Research Institute Of City Of Hope Specific hybridoma cell line and monocolonal antibodies produced from such specific hybridoma cell line and method of using such monoclonal antibodies to detect carcinoembryonic antigens
US4963539A (en) * 1987-09-10 1990-10-16 E. R. Squibb & Sons, Inc. Phosphonate and phosphonamide endopeptidase inhibitors
US5153226A (en) * 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
DK0721449T3 (da) 1993-10-01 2002-04-22 Merrell Pharma Inc Inhibitorer af beta-amyloidproteinproduktion
GB9409150D0 (en) * 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
US5597845A (en) 1994-06-20 1997-01-28 Merrell Pharmaceuticals Inc. Substituted alkyldiamine derivatives
US5939526A (en) 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
CA2217006C (fr) 1995-04-13 2001-05-22 Hoechst Marion Roussel, Inc. Nouveaux derives de piperazine substitues presentant une activite d'antagonistes des recepteurs de la tachykinine
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
WO1997039121A1 (fr) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Peptides du recepteur de produits terminaux d'une glycosylation avancee, et utilisation de ces peptides
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US5688653A (en) 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US5922770A (en) * 1996-07-22 1999-07-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6004958A (en) 1997-02-05 1999-12-21 Fox Chase Cancer Center Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
US6100098A (en) 1997-02-18 2000-08-08 Mcgill University Anti-AGE IgG and uses thereof for the diagnosis of severe disease
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
AU3376699A (en) 1998-03-31 1999-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
JP2002526117A (ja) 1998-10-06 2002-08-20 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 細胞外新規ｒａｇｅ結合タンパク質（ｅｎ−ｒａｇｅ）及びその使用
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂

Also Published As

Publication number Publication date
EP1284959B1 (fr) 2005-07-20
EP1642888A1 (fr) 2006-04-05
CA2379695A1 (fr) 2001-12-06
US20060189578A1 (en) 2006-08-24
CA2379695C (fr) 2007-11-27
ES2373557T3 (es) 2012-02-06
US7067554B2 (en) 2006-06-27
DE60112079D1 (de) 2005-08-25
US6613801B2 (en) 2003-09-02
ATE531688T1 (de) 2011-11-15
US20020006957A1 (en) 2002-01-17
MXPA02001099A (es) 2004-04-05
US20040097407A1 (en) 2004-05-20
DK1284959T3 (da) 2005-11-21
EP1284959A1 (fr) 2003-02-26
WO2001092210A1 (fr) 2001-12-06
EP1642888B1 (fr) 2011-11-02
AU780368B2 (en) 2005-03-17
ATE299860T1 (de) 2005-08-15
AU2005200425A1 (en) 2005-02-24
JP4451058B2 (ja) 2010-04-14
ES2243506T3 (es) 2005-12-01
AU6508301A (en) 2001-12-11
AU2005200425B2 (en) 2009-01-15
JP2004519416A (ja) 2004-07-02
US20060148760A1 (en) 2006-07-06
CA2599562A1 (fr) 2001-12-06
DE60112079T2 (de) 2006-06-01

Similar Documents

Publication Publication Date Title
HK1052338A1 (en) Compounds for modulating the rage receptor
WO2002070473A3 (fr) Derives de carboxamide utilises comme agents therapeutiques
WO2003075921A3 (fr) Derives de l'azole et derives bicycliques fusionnes de l'azole, agents therapeutiques
WO2005052002A3 (fr) Anticorps a un seul domaine et utilisations de celui-ci
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
BRPI0518322A2 (pt) composiÇço, kit, e, mÉtodos para tratar uma condiÇço, para reverter um efeito no sistema nervoso central de um agente, para tratar um animal de dor, e para controlar dor crânica
WO2003099771A3 (fr) Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2005007652A3 (fr) Analogues de quinoline-4-ylamine substituee
EP1262177A3 (fr) Utilisation médicale des composés thyromimétiques pour traiter la chute des cheveux et compositions
WO2005007648A3 (fr) Analogues de biaryl piperazinyl-pyridine
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
WO2003092617A3 (fr) Combinaisons destinees au traitement de troubles cutanes inflammatoires
WO2002058636A3 (fr) Nouveaux ligands cannabimimetiques
WO2004110151A8 (fr) Traitement du cancer au moyen de composes de vitamine d actifs associes a des agents et a des traitements radiotherapeutiques
WO2003017939A3 (fr) Composes de piperazinone utilises comme agents antitumoraux et anticancereux et procedes de traitement
WO2002098362A3 (fr) Utilisation d'antagonistes rank dans le traitement du cancer
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
AU2002222180A1 (en) The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
WO2002087503A3 (fr) Compositions et methodes de traitement des polypes colorectaux et du cancer colorectal
WO2004056768A3 (fr) Utilisation de 2,5-diamidoindoles substitues pour le traitement de maladies urologiques
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
WO2003028536A3 (fr) Methodes permettant de diagnostiquer et de traiter les maladies cardiaques
DE69720410D1 (de) Therapeutisches Mittel zur Behandlung hartnäckiger Hundedermatitis
WO2000043028A3 (fr) Therapie contre une affection cardiaque chronique

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140525